Th1/Th2 shift in patients with lymphoma compared with that in patients with solid tumor

( views:133, downloads:0 )
Author:
QIAO Li-juan(Department of Clinical Laboratory, Shanxi Cancer Hospital,Taiyuan 030013, China)
WU Xiao-ying(Department of Clinical Laboratory, Shanxi Cancer Hospital,Taiyuan 030013, China)
LI Yao-ping()
Journal Title:
CANCER RESEARCH AND CLINIC
Issue:
Volume 22, Issue z1, 2010
DOI:
10.3760/cma.j.issn.1006-9801.2010.增.003
Key Word:
Lymphoma, solid tumors;Th1/Th2, cytokine;Flow cytometry

Abstract: Objective To compare Th1/Th2 drift situation in patients with lymphoma with that in patients with solid tumors, and establish the effective immune function detectable criterion of lymphoma in biological treatment process. Methods The whole blood samples of 10 patients with lymphoma, 202 patients with solid tumors including 36 patients with upper digestive tract cancer, 64 colorectal cancer, 43 lung cancer and 20 the other malignancies, and 30 healthy persons as controls were collected. Stimulation agent was used to stimulate the cells in order to increase cell factor expression and fluorescent labeled specific anti-cytokine monoclonal antibody was used to bind with specific antigen. The expression of specific cytokines was detected by flow cytometry. Results Positive percentages of IFN- γ and IL-4 and ratio of IFN- γ /IL-4 in CD+4 T cells of human peripheral blood had statistically differences between in patients with lymphoma and controls (P < 0.05). The ratio of Thl/Th2 (CD+4 intracellular cytokine INF-α/IL-4) in patients with lymphoma was lower than that in patients with upper digestive tract cancers (esophagus and stomach cancers) (P = 0.023), however, had no statistical differences with that in patients with other solid tumors (colorectal, lung, kidney, breast and other tumors), but had a downward trend. Conclusion Immune functions in patients with lymphoma are lower than those in patients with solid tumors and immune treatment is a necessary to adjuvant chemotherapy. The ratio of Th1/Th2 (INF- α/IL-4) is expected to become effective detection criterion.

  • [1]吴平,陈捷,何惠娟,等.结肠癌患者外周血TH1/TH2细胞因子漂移及临床意义.实用医药杂志,2004,21:481-484.
  • [2]刘杰,田志刚.人肿瘤细胞中TH2类细胞因子的强势表达.中华肿瘤杂志,1998,20:105-107.
  • [3]于启海.郭宗远,吴荣德,等.小儿肾母细胞瘤TH1/TH2类因子的漂移及临床意义.山东医药,2001,41:19-21.
  • [4]钱莘.流式细胞技术检测细胞内细胞因子进展.细胞与分子生物学杂志,2005,21(Suppl).
  • [5]刘杰,魏海明,田志刚.TH1/TH2漂移与抗肿瘤免疫.国外医学肿瘤学分册,1997,24:168-170.
  • [6]Shurim MR,Lu L,Kalins P,et al.Th1/Th2 balance in cancer transplantantion and pregnancy.Springer Seminute Immunopathol,1999,21:339-359.
  • [7]E Romagnani S.Typel helper and Type2 helper cells function,regulation and role in protection and disease.Jnt J Clin Lab Res,1991,21:152-158.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn